Molecular marker and kit for predicting platinum-containing chemotherapy curative effects and lifetime of later-period non-small cell lung cancer

The invention belongs to the fields of medical molecular genetics and clinical medicine, and particularly relates to a molecular marker and a kit for predicting the clinical benefit rate and the progression-free survival of platinum-containing chemotherapy for later-period non-small cell lung cancer. The molecular marker comprises an RICTOR gene related to the clinical benefit rate and the progression-free survival of the platinum-containing chemotherapy for the later-period non-small cell lung cancer (NSCLC), and comprises a single-nucleotide polymorphism site rs6878291 on the gene. As an application of the molecular marker, the invention also provides the RICTOR gene polymorphism detection kit for an NSCLC patient prognostic the platinum-containing chemotherapy. The medical molecular and the kit can be used for predicting the clinical benefit rate and the progression-free survival of the platinum-containing chemotherapy for the later-period non-small cell lung cancer, and provides bases for individualized treatment of patients with the disease.